

Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use ([Clinical trial: Onco, Rare, Mental Health], RWE, Registry], End User, and Region - Global Forecast to 2029

<https://marketpublishers.com/r/EEDA2DA3C46BEN.html>

Date: February 2024

Pages: 413

Price: US\$ 4,950.00 (Single User License)

ID: EEDA2DA3C46BEN

Abstracts

The electronic clinical outcome assessment (eCOA) solutions market is projected to reach USD 3.9 billion by 2029 from USD 1.8 billion in 2024, at a CAGR 16.6% during the forecast period. The the growing inclination towards digital data collection and analysis, an escalating need for economical data collection solutions, and the increasing integration of connected devices in healthcare institutions are the factors that will drive the growth of this market. On the other hand, the sensitivity of patient health data requires robust security measures. Concerns about data breaches, unauthorized access, or cybersecurity threats may impede the adoption of eCOA solutions to a certain extent over the forecast period.

“The BYOD (bring your own device) model segment is estimated to hold the major share in 2023, by type of wearable, mobile and other devices.”

The wearable, mobile and other devices market is bifurcated into BYOD (bring your own device) model, provisioned device model, and hybrid model. The BYOD model segment accounted for the largest market share during the forecast period. The growth of BYOD (Bring Your Own Device) adoption is driven by cost-effectiveness, as it eliminates the need for sponsors to manage dedicated devices, lowering trial costs. Patient familiarity with their own devices enhances user-friendliness, boosting engagement and data quality, while increasing accessibility for geographically dispersed and resource-limited

patients, aligning with decentralized trials. Additionally, technological advancements in secure data encryption address security concerns, and evolving regulations favor secure BYOD implementation in certain regions, positioning it as a cost-efficient, patient-centric approach in clinical trials.

“Clinical trials segment is estimated to hold the largest share of electronic clinical outcome assessment (eCOA) solutions market, by application.”

Based on application, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into clinical trials, observational studies and real-world evidence (RWE) generation, patient management and registries, and other applications. The clinical trials segment is expected to hold the largest share during the forecast period. The rise of eCOA (Electronic Clinical Outcome Assessment) in clinical trials is driven by a myriad of advantages: heightened data quality achieved through real-time capture and minimized transcription errors, enhanced patient engagement facilitated by user-friendly platforms and improved data ownership, and increased trial efficiency through streamlined data collection and accelerated analysis. This results in superior-quality studies, increased patient satisfaction, and expedited drug development, positioning eCOA as the emerging gold standard for a more efficient, patient-centric future in clinical research.

“Electronic Observer-Reported Outcomes (EOBSRO) segment is expected to register highest growth in the forecast period, by product type segment.”

Based on product type, the Electronic Clinical Outcome Assessment (eCOA) Solutions market is segmented into electronic patient-reported outcomes (EPRO), Electronic Clinician-reported outcomes (ECLINRO), electronic observer-reported outcomes (EOBSRO), and Electronic performance-reported outcomes (EPERFO). In 2023, the electronic observer-reported outcomes (EOBSRO) segment is expected to register highest growth in the forecast period. Observer-reported outcomes (ObsRO) play a crucial role in gathering real-world evidence outside controlled trial settings, informing post-market research and regulatory decisions. Effective patient monitoring in decentralized trials, improved data quality, availability of holistic picture of patient experience and treatment response are some of the factors that contribute to the growth of the segment.

“Asia Pacific to register the highest growth in the electronic clinical outcome assessment (eCOA) solutions market in the forecast period.”

The global electronic clinical outcome assessment (eCOA) solutions market is segmented into four major regions, namely, North America, Europe, APAC, and the Rest of the World. In 2022, Asia Pacific was expected to register the highest growth for electronic clinical outcome assessment (eCOA) solutions systems in the forecast period. Factors such as increasing healthcare expenditure, developing healthcare infrastructure, rising demand for digital solutions in healthcare sector, large patient population, increasing focus on patient-centric care and the need for better data collection and analysis are expected to drive the growth of the electronic clinical outcome assessment (eCOA) solutions market in the Asia Pacific.

Breakdown of the supply-side, demand side, primary interviews by company type, designation, and region:

By Supply Side: Tier 1 (31%), Tier 2 (28%), and Tier 3 (41%)

By Demand Side: Hospital Directors/VPs/Managers/Department Heads (40%), Pharma & Biopharma Company's Product managers, Purchase Heads, etc. (35%), and Others (25%).

By Designation: C-level Executives (31%), Director-level (25%), and Managers (44%)

By Region: North America (45%), Europe (20%), Asia Pacific (28%), and RoW (4%)

The prominent players in this market are Koninklijke Signant Health (US), IQVIA Holdings, Inc. (US), Oracle (US), Clario (US), Medable Inc. (US), Medidata (US), Merative (US), ICON plc (Ireland), Paraxel International (MA) Corporation (US), Climedo Health GmbH (Germany), Healthentia (Belgium), Veeva Systems (US), assisTek (US), Curebase Inc. (US), Castor (US), EvidentIQ Group GmbH (Germany), YPrime, LLC. (US), Clinical ink (US), Clinion (US), Kayentis (France), TransPerfect (US), ObvioHealth USA, Inc. (US), WCG Clinical (Germany), ClinCapture (US), and Cloudbyz (US). Players adopted organic as well as inorganic growth strategies such as product launches and enhancements, and investments, partnerships, collaborations, joint ventures, funding, acquisition, expansions, agreements, sales contracts, and alliances to increase their offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Research Coverage

The report studies the electronic clinical outcome assessment (eCOA) solutions market based on component, product type, deployment model, application area, end user, and region.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.

The report studies micro-markets with respect to their growth trends, prospects, and contributions to the total electronic clinical outcome assessment (eCOA) solutions market.

The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

Analysis of key drivers (increasing R&D expenditure for product development by medtech, and pharma-biotech companies, rising operational costs and regulatory requirements associated with clinical research studies, favorable government support and funding for clinical trials, growing prevalence of chronic diseases & subsequent increase in clinical trials, effective monitoring of clinical data, reduction in overall costs and timelines of clinical trials), restraints (lack of skilled professionals to develop and operate eCOA solutions, high implementation and maintenance cost, lack of awareness about eCOA solutions among end users), opportunities (surging eCOA adoption owing to increasing

number of clinical trials in emerging economies, growing outsourcing of clinical trial processes to CROs, gradual shift from manual data interpretation to real-time data analysis, growing penetration of mobile technology in healthcare industry), and challenges (evolving regulatory landscape and compliance requirements, interoperability & integration, data security & privacy issues, resistance from traditional healthcare professionals and concerns regarding software reliability) influencing the growth of electronic clinical outcome assessment (eCOA) solutions market.

Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the electronic clinical outcome assessment (eCOA) solutions market.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of electronic clinical outcome assessment (eCOA) solutions across regions.

Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the electronic clinical outcome assessment (eCOA) solutions market.

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the electronic clinical outcome assessment (eCOA) solutions market.

Contents

1 INTRODUCTION

1.1 STUDY OBJECTIVES

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS

1.3 MARKET SCOPE

1.3.1 MARKET SEGMENTATION

FIGURE 1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET SEGMENTATION

1.3.2 REGIONAL SCOPE

1.4 YEARS CONSIDERED

1.4.1 CURRENCY CONSIDERED

TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD

1.5 STAKEHOLDERS

1.6 RECESSION IMPACT

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

FIGURE 2 RESEARCH DESIGN

2.2 SECONDARY SOURCES

2.2.1 KEY DATA FROM SECONDARY SOURCES

2.3 PRIMARY DATA

2.3.1 PRIMARY SOURCES

2.3.1.1 Key data from primary sources

2.3.1.2 Key industry insights

2.3.2 BREAKDOWN OF PRIMARY INTERVIEWS

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY CATEGORY, DESIGNATION, AND REGION

2.4 RESEARCH METHODOLOGY DESIGN

FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

2.5 MARKET SIZE ESTIMATION

FIGURE 5 SUPPLY-SIDE MARKET ESTIMATION: REVENUE SHARE ANALYSIS

2.5.1 BOTTOM-UP APPROACH

FIGURE 6 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: BOTTOM-UP APPROACH

FIGURE 7 DEMAND-SIDE APPROACH: END-USER SPENDING ON ELECTRONIC

CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

2.5.2 TOP-DOWN APPROACH

FIGURE 8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS
MARKET: TOP-DOWN APPROACH

TABLE 2 FACTOR ANALYSIS

FIGURE 9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS
MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES

FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.6 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 11 DATA TRIANGULATION METHODOLOGY

2.7 ASSUMPTIONS

2.7.1 MARKET SIZING ASSUMPTIONS

2.7.2 OVERALL STUDY ASSUMPTIONS

2.8 LIMITATIONS

2.8.1 SCOPE-RELATED LIMITATIONS

2.8.2 METHODOLOGY-RELATED LIMITATIONS

2.9 RISK ASSESSMENT

TABLE 3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS
MARKET: RISK ASSESSMENT

2.10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS
MARKET: RECESSION IMPACT ANALYSIS

TABLE 4 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)

TABLE 5 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)

TABLE 6 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)

3 EXECUTIVE SUMMARY

FIGURE 12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)
SOLUTIONS MARKET, BY COMPONENT, 2024 VS. 2029 (USD MILLION)

FIGURE 13 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)
SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER
DEVICES, BY MODEL, 2024 VS. 2029 (USD MILLION)

FIGURE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)
SOLUTIONS MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)

FIGURE 15 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)
SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2029 (USD MILLION)

FIGURE 16 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)
SOLUTIONS MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)

FIGURE 17 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)

FIGURE 18 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)

FIGURE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

4.1 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET OVERVIEW

FIGURE 20 GOVERNMENT INITIATIVES & SURGING R&D EXPENDITURES TO DRIVE MARKET GROWTH

4.2 ASIA PACIFIC: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY PRODUCT AND COUNTRY (2023)

FIGURE 21 JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023

4.3 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

FIGURE 22 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD

4.4 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: REGIONAL MIX (2021?2029)

FIGURE 23 NORTH AMERICA TO CONTINUE TO DOMINATE ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET DURING FORECAST PERIOD

4.5 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: DEVELOPED VS. EMERGING ECONOMIES

FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 MARKET DYNAMICS: IMPACT ANALYSIS

5.2.2 DRIVERS

5.2.2.1 Increasing R&D expenditure for product development by medtech and pharma-biotech companies

FIGURE 26 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028

5.2.2.2 Rising operational costs and regulatory requirements associated with clinical research studies

5.2.2.3 Favorable government support and funding for clinical trials

5.2.2.4 Growing prevalence of chronic diseases & subsequent increase in clinical trials

5.2.2.5 Effective monitoring of clinical data

5.2.2.6 Reduction in overall costs and timelines of clinical trials

5.2.3 RESTRAINTS

5.2.3.1 Dearth of skilled professionals to develop and operate eCOA solutions

5.2.3.2 High implementation and maintenance costs

5.2.3.3 Lack of awareness about eCOA solutions among end users

5.2.4 OPPORTUNITIES

5.2.4.1 Surging eCOA adoption owing to increasing number of clinical trials in emerging economies

5.2.4.2 Growing outsourcing of clinical trial processes to CROs

5.2.4.3 Gradual shift from manual data interpretation to real-time data analysis

5.2.4.4 Growing penetration of mobile technology in healthcare industry

5.2.5 CHALLENGES

5.2.5.1 Evolving regulatory landscape and compliance requirements

5.2.5.2 Concerns regarding data security & privacy

5.2.5.3 Lack of interoperability & integration

5.2.5.4 Resistance from traditional healthcare professionals and concerns regarding software reliability

6 INDUSTRY INSIGHTS

6.1 INTRODUCTION

6.2 OVERVIEW OF KEY INDUSTRY TRENDS

6.2.1 RISING NUMBER OF DECENTRALIZED CLINICAL TRIALS

6.2.2 INCREASED FOCUS ON REAL-WORLD DATA (RWD)

6.3 VALUE/SUPPLY CHAIN ANALYSIS

FIGURE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (eCOA) SOLUTIONS MARKET: VALUE CHAIN ANALYSIS (2023)

6.4 ECOSYSTEM ANALYSIS

FIGURE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)

SOLUTIONS MARKET: ECOSYSTEM ANALYSIS (2023)

6.5 TECHNOLOGY ANALYSIS

6.5.1 KEY TECHNOLOGIES

6.5.1.1 Machine learning

6.5.1.2 Artificial intelligence

6.5.1.3 Internet of things

6.5.1.4 Integrated APIs

6.5.2 COMPLEMENTARY TECHNOLOGIES

6.5.2.1 Interactive Voice Response (IVR)

6.5.2.2 Data analytics

6.5.2.3 Telehealth

6.5.3 ADJACENT TECHNOLOGIES

6.5.3.1 Cloud computing

6.5.3.2 Blockchain

6.6 REGULATORY LANDSCAPE

6.6.1 REGULATORY ANALYSIS

6.6.1.1 North America

6.6.1.2 Europe

6.6.1.3 Asia Pacific

6.6.1.4 Latin America

6.6.1.5 Middle East & Africa

6.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 10 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

6.7 PORTER'S FIVE FORCES ANALYSIS

TABLE 11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: PORTER'S FIVE FORCES ANALYSIS

6.7.1 COMPETITIVE RIVALRY

6.7.2 BARGAINING POWER OF BUYERS

6.7.3 BARGAINING POWER OF SUPPLIERS

6.7.4 THREAT OF SUBSTITUTES

6.7.5 THREAT OF NEW ENTRANTS

6.8 PRICING ANALYSIS

6.8.1 AVERAGE SELLING PRICE TREND, BY REGION

6.8.2 INDICATIVE PRICING ANALYSIS, BY PRODUCT

TABLE 12 AVERAGE SELLING PRICE OF ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS, BY SOLUTION TYPE (2023)

6.9 CASE STUDY ANALYSIS

6.9.1 CASE 1: A LEADING ACADEMIC MEDICAL CENTER MONITORS NEWLY DIAGNOSED MYELOMA PATIENTS WITH MEDIDATA ECO

6.9.2 CASE 2: SIGNANT'S SCALE MANAGEMENT EXPERTISE FACILITATES ENDPOINT ACCURACY & RELIABILITY IN PSORIATIC ARTHRITIS TRIAL

6.10 PATENT ANALYSIS

FIGURE 29 TOP PATENT OWNERS AND APPLICANTS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS (JANUARY 2011–JANUARY 2024)

FIGURE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: PATENT ANALYSIS (JANUARY 2011–JANUARY 2024)

FIGURE 31 TOP APPLICANT COUNTRIES/REGIONS FOR ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTION PATENTS (JANUARY 2011–JANUARY 2024)

TABLE 13 LIST OF PATENTS/PATENT APPLICATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, 2021–2023

6.11 KEY CONFERENCES & EVENTS, 2023–2024

TABLE 14 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET: DETAILED LIST OF CONFERENCES & EVENTS

6.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 32 REVENUE SHIFT IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET

6.13 KEY STAKEHOLDERS & BUYING CRITERIA

6.13.1 KEY STAKEHOLDERS IN BUYING PROCESS

FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP 3 END USERS

TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE END USERS

6.13.2 BUYING CRITERIA

FIGURE 34 KEY BUYING CRITERIA FOR END USERS

TABLE 16 KEY BUYING CRITERIA FOR END USERS

6.14 END-USER ANALYSIS

6.14.1 UNMET NEEDS

TABLE 17 UNMET NEEDS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET

6.14.2 END-USER EXPECTATIONS

TABLE 18 END-USER EXPECTATIONS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET

6.15 REVENUE MODEL ANALYSIS

6.15.1 SUBSCRIPTION-BASED MODEL

6.15.2 PAY-PER-STUDY MODEL

6.15.3 CUSTOMIZED SOLUTIONS MODEL

6.15.4 SOFTWARE-AS-A-SERVICE (SAAS) MODEL

6.15.5 CONSULTING AND INTEGRATION SERVICES MODEL

6.16 INVESTMENT LANDSCAPE

FIGURE 35 RECENT INVESTMENTS IN ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET

7 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT

7.1 INTRODUCTION

TABLE 19 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)

TABLE 20 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)

7.2 SOFTWARE

7.2.1 ADVANTAGES OF ECOA SOFTWARE LIKE REAL-TIME ANALYSIS AND STREAMLINED DATA COLLECTION TO FOSTER MARKET GROWTH

TABLE 21 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 22 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SOFTWARE, BY COUNTRY, 2023–2029 (USD MILLION)

7.3 SERVICES

7.3.1 ABILITY OF ECOA SERVICES TO REDUCE TIME AND COST OF CLINICAL TRIAL PROCESSES TO BOOST DEMAND

TABLE 23 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 24 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR SERVICES, BY COUNTRY, 2023–2029 (USD MILLION)

7.4 WEARABLES, MOBILE DEVICES, AND OTHER DEVICES

TABLE 25 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018–2022 (USD MILLION)

TABLE 26 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023–2029 (USD MILLION)

TABLE 27 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 28 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY COUNTRY, 2023–2029 (USD MILLION)

7.4.1 BRING YOUR OWN DEVICE (BYOD) MODEL

7.4.1.1 Ability of BYOD models to increase flexibility and convenience to drive adoption

TABLE 29 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 30 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR BRING YOUR OWN DEVICE (BYOD) MODELS, BY COUNTRY, 2023–2029 (USD MILLION)

7.4.2 PROVISIONED DEVICE MODEL

7.4.2.1 Growing need for standardization and control in data collection process to support market growth

TABLE 31 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 32 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR PROVISIONED DEVICE MODELS, BY COUNTRY, 2023–2029 (USD MILLION)

7.4.3 HYBRID MODEL

7.4.3.1 Ability of hybrid models to increase balance between standardization and participant preferences to favor growth

TABLE 33 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 34 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR HYBRID MODELS, BY COUNTRY, 2023–2029 (USD MILLION)

8 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET, BY PRODUCT

8.1 INTRODUCTION

TABLE 35 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)

TABLE 36 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)

8.2 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO)

8.2.1 GROWING EMPHASIS ON PATIENT-CENTRIC HEALTHCARE TO BOOST MARKET GROWTH

TABLE 37 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 38 ELECTRONIC PATIENT-REPORTED OUTCOMES (EPRO) MARKET, BY COUNTRY, 2023–2029 (USD MILLION)

8.3 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO)

8.3.1 GROWING NEED FOR ACCURATE AND RELIABLE DATA COLLECTION TO DRIVE ADOPTION OF EOBSRO SOLUTIONS

TABLE 39 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 40 ELECTRONIC OBSERVER-REPORTED OUTCOMES (EOBSRO) MARKET, BY COUNTRY, 2023–2029 (USD MILLION)

8.4 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO)

8.4.1 INCREASING EFFICACY AND ACCURACY IN CAPTURING CLINICIAN-REPORTED DATA TO PROPEL GROWTH

TABLE 41 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 42 ELECTRONIC CLINICIAN-REPORTED OUTCOMES (ECLINRO) MARKET, BY COUNTRY, 2023–2029 (USD MILLION)

8.5 ELECTRONIC PERFORMANCE-REPORTED OUTCOME (EPERFO)

8.5.1 INCREASING ACCESSIBILITY AND FLEXIBILITY IN CLINICAL TRIAL SETTINGS TO BOOST MARKET

TABLE 43 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 44 ELECTRONIC PERFORMANCE-REPORTED OUTCOMES (EPERFO) MARKET, BY COUNTRY, 2023–2029 (USD MILLION)

9 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL

9.1 INTRODUCTION

TABLE 45 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)

TABLE 46 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)

9.2 ON-PREMISE MODEL

9.2.1 OPTIMAL CONTROL ON DEPLOYMENT AND DATA BACKUP TO SUPPORT MARKET UPTAKE

TABLE 47 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2018–2022 (USD MILLION)

TABLE 48 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR ON-PREMISE MODELS, BY REGION, 2023–2029 (USD MILLION)

9.3 WEB-HOSTED & CLOUD-BASED MODEL

9.3.1 ENHANCED QUALITY OF CLINICAL TRIALS WITH IMPROVED PRODUCTIVITY TO DRIVE MARKET

TABLE 49 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2018–2022 (USD MILLION)

TABLE 50 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEB-HOSTED & CLOUD-BASED MODELS, BY REGION, 2023–2029 (USD MILLION)

9.4 HYBRID MODEL

9.4.1 ABILITY TO OFFER BALANCED SOLUTIONS USING HYBRID MODEL TO SUPPORT MARKET GROWTH

TABLE 51 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2018–2022 (USD MILLION)

TABLE 52 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR HYBRID MODELS, BY REGION, 2023–2029 (USD MILLION)

10 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION

10.1 INTRODUCTION

TABLE 53 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)

TABLE 54 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)

10.2 CLINICAL TRIALS

TABLE 55 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS

MARKET, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)

TABLE 56 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET, BY THERAPEUTIC AREAS, 2023–2029 (USD MILLION)

TABLE 57 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 58 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR CLINICAL TRIALS, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.1 ONCOLOGY

10.2.1.1 Rising incidence of cancer to drive market growth

FIGURE 36 US: CANCER INCIDENCE IN MALES, BY TYPE (2022)

FIGURE 37 US: CANCER INCIDENCE IN FEMALES, BY TYPE (2022)

FIGURE 38 GLOBAL ONCOLOGY CLINICAL TRIALS, 2010–2021 (THOUSAND)

TABLE 59 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR ONCOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 60 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.2 INFECTIOUS DISEASES

10.2.2.1 Growing focus on infectious disease treatment and management to boost market

TABLE 61 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 62 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.3 NEUROLOGY

10.2.3.1 Increasing investments in R&D and grants for neurological disorders to drive market

TABLE 63 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR NEUROLOGY, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 64 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR NEUROLOGY, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.4 METABOLIC DISORDERS

10.2.4.1 Rising diabetes incidence to drive market

FIGURE 39 INCREASE IN DIABETES CASES, 2000–2045 (MILLION INDIVIDUALS)

TABLE 65 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 66 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS

MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.5 IMMUNOLOGY

10.2.5.1 Increasing development of immunology drugs to drive demand for eCOA

solutions

TABLE 67 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 68 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR IMMUNOLOGY, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.6 CARDIOVASCULAR DISEASES

10.2.6.1 Need for efficient and reliable means of collecting patient-reported outcomes in cardiovascular trials to support growth

TABLE 69 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 70 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.7 RARE DISEASES & GENETIC DISORDERS

10.2.7.1 Growing government support for rare diseases & genetic disorders to boost market

TABLE 71 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 72 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR RARE DISEASES & GENETIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.8 MENTAL HEALTH DISORDERS

10.2.8.1 Growing awareness of mental health disorders to contribute to market growth

TABLE 73 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 74 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR MENTAL HEALTH DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION)

10.2.9 OTHER THERAPEUTIC AREAS

TABLE 75 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 76 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2023–2029 (USD MILLION)

10.3 OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION

10.3.1 GROWING RECOGNITION OF BENEFITS OF REAL-WORLD EVIDENCE

GENERATION TO DRIVE DEMAND

TABLE 77 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 78 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OBSERVATIONAL STUDIES & REAL-WORLD EVIDENCE (RWE) GENERATION, BY COUNTRY, 2023–2029 (USD MILLION)

10.4 PATIENT MANAGEMENT & REGISTRIES

10.4.1 EVOLVING LANDSCAPE OF PATIENT-CENTRIC HEALTHCARE TO DRIVE SEGMENTAL GROWTH

TABLE 79 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 80 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PATIENT MANAGEMENT & REGISTRIES, BY COUNTRY, 2023–2029 (USD MILLION)

10.5 OTHER APPLICATIONS

TABLE 81 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 82 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2029 (USD MILLION)

11 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER

11.1 INTRODUCTION

TABLE 83 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)

TABLE 84 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)

11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

11.2.1 INCREASING R&D EXPENDITURE FOR DRUG DISCOVERY AND DEVELOPMENT TO DRIVE MARKET

TABLE 85 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 86 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS

MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)

11.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)

11.3.1 RISING OUTSOURCING OF CLINICAL TRIAL ACTIVITIES TO CROS BY PHARMACEUTICAL COMPANIES TO DRIVE MARKET

TABLE 87 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 88 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2023–2029 (USD MILLION)

11.4 GOVERNMENT ORGANIZATIONS

11.4.1 GROWING COLLABORATIONS BETWEEN GOVERNMENT ORGANIZATIONS AND CROS TO PROPEL GROWTH

TABLE 89 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 90 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR GOVERNMENT ORGANIZATIONS, BY COUNTRY, 2023–2029 (USD MILLION)

11.5 MEDTECH COMPANIES

11.5.1 GROWING UTILIZATION OF CLINICAL DATA SOFTWARE SOLUTIONS FOR MEDICAL DEVICE TRIALS TO FUEL GROWTH

TABLE 91 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 92 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR MEDTECH COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)

11.6 HOSPITALS & HEALTHCARE PROVIDERS

11.6.1 INCREASING IT BUDGETS TO STREAMLINE PATIENT DATABASES TO PROPEL MARKET GROWTH

TABLE 93 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 94 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR HOSPITALS & HEALTHCARE PROVIDERS, BY COUNTRY, 2023–2029 (USD MILLION)

11.7 ACADEMIC & RESEARCH INSTITUTES

11.7.1 FAVORABLE GOVERNMENT SUPPORT FOR CLINICAL RESEARCH TO SUPPORT MARKET GROWTH

TABLE 95 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 96 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2029 (USD MILLION)

11.8 CONSULTING SERVICE COMPANIES

11.8.1 GROWING COLLABORATIONS BETWEEN CONSULTANCY FIRMS AND PHARMA & BIOTECH COMPANIES TO DRIVE MARKET

TABLE 97 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 98 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CONSULTING SERVICE COMPANIES, BY COUNTRY, 2023–2029 (USD MILLION)

12 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY REGION

12.1 INTRODUCTION

TABLE 99 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY REGION, 2018–2022 (USD MILLION)

TABLE 100 ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY REGION, 2023–2029 (USD MILLION)

12.2 NORTH AMERICA

FIGURE 40 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET SNAPSHOT

TABLE 101 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COUNTRY, 2018–2022 (USD MILLION)

TABLE 102 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COUNTRY, 2023–2029 (USD MILLION)

TABLE 103 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)

TABLE 104 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)

TABLE 105 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018–2022 (USD MILLION)

TABLE 106 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT

(ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023–2029 (USD MILLION)

TABLE 107 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)

TABLE 108 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)

TABLE 109 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)

TABLE 110 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)

TABLE 111 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)

TABLE 112 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)

TABLE 113 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)

TABLE 114 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)

TABLE 115 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)

TABLE 116 NORTH AMERICA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)

12.2.1 NORTH AMERICA: RECESSION IMPACT

12.2.2 US

12.2.2.1 Rising government funding for pharmaceutical R&D to drive market

FIGURE 41 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION (2021 VS. 2022)

TABLE 117 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)

TABLE 118 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)

TABLE 119 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018–2022 (USD MILLION)

TABLE 120 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO)

SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023–2029 (USD MILLION)

TABLE 121 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)

TABLE 122 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)

TABLE 123 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)

TABLE 124 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)

TABLE 125 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)

TABLE 126 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)

TABLE 127 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022 (USD MILLION)

TABLE 128 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029 (USD MILLION)

TABLE 129 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)

TABLE 130 US: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)

12.2.3 CANADA

12.2.3.1 Increasing number of clinical trials to support market growth

TABLE 131 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2018–2022 (USD MILLION)

TABLE 132 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY COMPONENT, 2023–2029 (USD MILLION)

TABLE 133 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2018–2022 (USD MILLION)

TABLE 134 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET FOR WEARABLES, MOBILE DEVICES, AND OTHER DEVICES, BY MODEL, 2023–2029 (USD MILLION)

TABLE 135 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA) SOLUTIONS MARKET, BY PRODUCT, 2018–2022 (USD MILLION)

TABLE 136 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECOA)

SOLUTIONS MARKET, BY PRODUCT, 2023–2029 (USD MILLION)

TABLE 137 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2018–2022 (USD MILLION)

TABLE 138 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2023–2029 (USD MILLION)

TABLE 139 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY APPLICATION, 2018–2022 (USD MILLION)

TABLE 140 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY APPLICATION, 2023–2029 (USD MILLION)

TABLE 141 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2018–2022
(USD MILLION)

TABLE 142 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET FOR CLINICAL TRIALS, BY THERAPEUTIC AREA, 2023–2029
(USD MILLION)

TABLE 143 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY END USER, 2018–2022 (USD MILLION)

TABLE 144 CANADA: ELECTRONIC CLINICAL OUTCOME ASSESSMENT (ECO A)

SOLUTIONS MARKET, BY END USER, 2023–2029 (USD MILLION)

I would like to order

Product name: Electronic Clinical Outcome Assessment (eCOA) Solution Market by Modality (Wearable, Mobile, BYOD), Type (PRO, CLINRO, OBSRO, PERFO), Use ([Clinical trial: Onco, Rare, Mental Health], RWE, Registry], End User, and Region - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/EEDA2DA3C46BEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EEDA2DA3C46BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970